Biologie Neurovasculaire et Mitochondriale Intégrée, UMR CNRS 6214 INSERM 1083, Université d'Angers, France.
Cardiovasc Res. 2012 Jul 15;95(2):223-32. doi: 10.1093/cvr/cvs152. Epub 2012 May 24.
Blood flow autoregulation results from the ability of resistance arteries to reduce or increase their diameters in response to changes in intravascular pressure. The mechanism by which arteries maintain a constant blood flow to organs over a range of pressures relies on this myogenic response, which defines the intrinsic property of the smooth muscle to contract in response to stretch. The resistance to flow created by myogenic tone (MT) prevents tissue damage and allows the maintenance of a constant perfusion, despite fluctuations in arterial pressure. Interventions targeting MT may provide a more rational therapeutic approach in vascular disorders, such as hypertension, vasospasm, chronic heart failure, or diabetes. Despite its early description by Bayliss in 1902, the cellular and molecular mechanisms underlying MT remain poorly understood. We now appreciate that MT requires a complex mechanotransduction converting a physical stimulus (pressure) into a biological response (change in vessel diameter). Although smooth muscle cell depolarization and a rise in intracellular calcium concentration are recognized as cornerstones of the myogenic response, the role of wall strain-induced formation of vasoactive mediators is less well established. The vascular system expresses a large variety of Class 1 G protein-coupled receptors (GPCR) activated by an eclectic range of chemical entities, including peptides, lipids, nucleotides, and amines. These messengers can function in blood vessels as vasoconstrictors. This review focuses on locally generated GPCR agonists and their proposed contributions to MT. Their interplay with pivotal G(q-11) and G(12-13) protein signalling is also discussed.
血流自动调节是由于阻力血管能够根据血管内压力的变化来减少或增加其直径。动脉在一定压力范围内保持器官恒定血流的机制依赖于这种肌源性反应,它定义了平滑肌对拉伸的收缩固有特性。肌源性张力(MT)产生的血流阻力可防止组织损伤,并允许在动脉压波动的情况下保持恒定的灌注。针对 MT 的干预措施可能为血管疾病(如高血压、血管痉挛、慢性心力衰竭或糖尿病)提供更合理的治疗方法。尽管 Bayliss 早在 1902 年就对其进行了描述,但 MT 的细胞和分子机制仍知之甚少。我们现在认识到,MT 需要一个复杂的机械转导过程,将物理刺激(压力)转化为生物反应(血管直径的变化)。尽管平滑肌细胞去极化和细胞内钙离子浓度升高被认为是肌源性反应的基石,但壁应变诱导血管活性介质形成的作用尚未得到充分证实。血管系统表达了大量的第一类 G 蛋白偶联受体(GPCR),它们被各种化学实体激活,包括肽、脂质、核苷酸和胺。这些信使可以作为血管收缩剂在血管中发挥作用。本综述重点介绍了局部产生的 GPCR 激动剂及其对 MT 的可能贡献。还讨论了它们与关键的 G(q-11)和 G(12-13)蛋白信号的相互作用。